MTOR and Cognitive impairment: Therapeutic efficacy of ALA has been observed in animal models of stroke [114–119] that improves outcome [120], spinal cord injury [121], kainic acid-induced status epilepticus [81], a temporal lobe epilepsy model, after soman-induced status epilepticus [122] that reduces behavioral and cognitive impairment [123, 124] in part via an mammalian target of rapamycin-mediated mechanism [125] and in a mild traumatic brain injury model [126].